课题基金 / 基金详情

项目摘要

项目成果

MARTHA S JORDAN的其他基金

相似基金

相关文献

中文摘要
翻译
T细胞在适应性免疫反应中起着关键作用。然而,当连续
英文摘要
T cells are pivotal players in the adaptive immune response. However, when continuously exposed to antigen, as in persistent infection or cancer, T cells lose effector function and ultimately become exhausted, leading to chronic infection or progressive disease. Recent therapeutic advances are based on reversing these natural mechanisms set in place to “quiet” activated T cells during the resolution phase of an immune response, and in doing so, reinvigorate immune responses crippled by T cell exhaustion. However, response rates remain low in many settings; thus, additional strategies are needed. Crucial for developing such strategies is to identify new targetable pathways, which is currently hampered by our limited basic knowledge of the negative regulatory pathways that inhibit T cell activation. We recently discovered that the pseudokinase Trib1 is a novel negative regulator of T cell activation, which is induced upon T cell receptor (TCR) stimulation. Our overall goal is to determine the cellular and molecular mechanisms by which Trib1 regulates T cell responses. Our preliminary data generated both in vitro and in vivo suggest that in the absence of Trib1, T cells are hyper-activated and are better able to control chronic infections. Mechanistically, Trib1 appears to exert its effects on T cells via a novel mechanism of regulating NF-κB. Based on these preliminary data, our overarching hypothesis is that Trib1 suppresses signaling pathways that promote T cell activation and promotes immune cell exhaustion by limiting T cell effector function and B cell help. This hypothesis will be tested in two aims: Aim 1 will define the cellular responses regulated by Trib1, and Aim 2 will determine the signaling pathways responsible for these findings. Our findings may lead to new insights into controlling T cell activation and exhaustion in multiple scenarios, including chronic infections and cancer, and in doing so, identify new avenues for therapeutic interventions.
期刊论文(38)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1371/journal.pone.0030656
发表时间: 2012
期刊: PloS one
影响因子: 3.7
作者: [Pan X, Jones M, Jiang J, Zaprazna K, Yu D, Pear W, Maillard I, Atchison ML]
通讯作者: Atchison ML
The transcriptional coactivator Maml1 is required for Notch2-mediated marginal zone B-cell development.
Notch2 介导的边缘区 B 细胞发育需要转录共激活因子 Maml1。
DOI: 10.1182/blood-2007-06-097030
发表时间: 2007
期刊: Blood
影响因子: 20.3
作者: [Wu,Lizi, Maillard,Ivan, Nakamura,Makoto, Pear,WarrenS, Griffin,JamesD]
通讯作者: Griffin,JamesD
DOI: 10.1038/leu.2011.127
发表时间: 2011-10
期刊: Leukemia
影响因子: 11.4
作者: [Pajcini KV, Speck NA, Pear WS]
通讯作者: Pear WS
DOI: 10.1146/annurev-pathol-052016-100127
发表时间: 2017-01-24
期刊: Annual review of pathology
影响因子: --
作者: [Aster JC, Pear WS, Blacklow SC]
通讯作者: Blacklow SC
共 16 条
    Transcriptional Checkpoints Of Autoimmune Encephalomyelitis
    • 批准号:
      10521303
    • 项目类别:
    • 资助金额:
      $50.12万
    • 财政年份:
      2019
    • 负责人:
      MARTHA S JORDAN
    • 依托单位:
    The role of SLP-76 phosphorylation in T cell development
    • 批准号:
      7270073
    • 项目类别:
    • 资助金额:
      $12.76万
    • 财政年份:
      2006
    • 负责人:
      MARTHA S JORDAN
    • 依托单位:
    The role of SLP-76 phosphorylation in T cell development
    • 批准号:
      7485035
    • 项目类别:
    • 资助金额:
      $12.76万
    • 财政年份:
      2006
    • 负责人:
      MARTHA S JORDAN
    • 依托单位:
    The role of SLP-76 phosphorylation in T cell development
    • 批准号:
      8123426
    • 项目类别:
    • 资助金额:
      $12.76万
    • 财政年份:
      2006
    • 负责人:
      MARTHA S JORDAN
    • 依托单位:
    国内基金
    海外基金
    Agonist-GPR119-Gs复合物的结构生物学研究
    • 批准号:
      32000851
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      24.0万元
    • 批准年份:
      2020
    • 负责人:
      乔安娜
    • 依托单位: